This study provided the mechanistic support for combinatorial treatment (MEK plus histone deacetylase inhibitors) for KRAS-mutant lung cancer, and, again, highlighted the importance of stratification of epithelial and mesenchymal subsets in decision-making for treating KRAS-mutant lung cancer. Here, KRAS is linked to lung cancer.